Duke RAVA Sitnib and Psoriatic Arthritis

FDA's major role is to protect the population. We should be cognizant that these adverse events can occur and probably the ones that have gained the most notoriety has been the issue of serious infections, malignancies, death, cardiovascular events and also clotting events. Those have been seen across the jack class we just don't know whether it's equally applicable to every single one of the jacks that are currently in the marketplace or being studied. That brings me to my next question. You mentioned Duke out of Sitnib earlier which was recently approved to treat psoriasis and doesn't have a lot of adverse effects so how does it work compared to other jack inhibitors? Do you